Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 25 of 1,261
  1. US 12370256

    Activation of resident memory T cells for the treatment of cancer

    Regents of the University of Minnesota · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  2. US 12370188

    Formulations of dazucorilant, a glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  3. US 12369604

    Methods of inhibition with microbial strains and antibiotics

    MICROBIAL DISCOVERY GROUP, LLC · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  4. US 12370257

    Materials and methods of treating MHC-I-opathy risk haplotypes

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  5. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  6. US 12370241

    Nasal powder formulation for treatment of hypoglycemia

    Amphastar Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  7. US 12370181

    Regimens of estrogen receptor antagonists

    Olema Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  8. US 12371500

    Il-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  9. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  10. US 12370163

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  11. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  12. US 12371414

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  13. US 12371333

    Purification of clinoptilolite

    Revelation Health LLC · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  14. US 12370266

    Polymer composite nanomaterial encapsulation system

    Core Quantum, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  15. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  16. US 12370255

    Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  17. US 12370194

    Metalloenzyme inhibitor compounds

    Eikonizo Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  18. US 12370245

    ALK polypeptides and methods of use thereof

    Elicio Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  19. US 12371442

    Isoindolinone and indazole compounds for the degradation of EGFR

    C4 THERAPEUTICS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  20. US 12370261

    Chimeric peptides for antisense delivery

    Sarepta Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  21. US 12370232

    Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition

    Poly Gain Pte Ltd · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  22. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  23. US 12370206

    Therapy for inhibition of single-stranded RNA virus replication

    RedHill Biopharma Ltd. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  24. US 12370229

    Methods of treating bladder cancer

    CG ONCOLOGY, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.